PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sanofi, miRecule join forces

Sanofi and next-gen RNA biotech miRecule announced this week a new partnership and licensing agreement for the development of an antibody-RNA conjugate (ARC) treatment for facioscapulohumeral muscular dystrophy (FSHD).

MiRecule is relatively young biotech, founded in 2016 and headquartered in Gaithersburg, Maryland. As part of the new collaboration, the two companies will work together using miRecule’s proprietary DREAmiR platform which uses genomic analysis to develop targeted RNA therapies in combination with Sanofi’s proprietary muscle-targeted NANOBODY technology.

As a first endeavour, the companies announced that they will use miRecule’s DUX4 RNA therapy with Sanofi’s technology to join two molecules into an ARC to produce a “potential best-in-class” disease-modifying treatment for the otherwise progressive and debilitating disease. Patients living with FSHD — roughly 870,000 worldwide — face lifelong muscle function deterioration, and currently, there is no treatment to slow down or cure it.

In exchange for an exclusive worldwide license to intellectual property rights to the FSHD therapy developed, miRecule will receive an upfront payment and near-term milestone payments nearing $30 million combined. Future regulatory, development and commercial milestone payments could make it closer to $400 million.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026